Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIM2 | Q9P1W9 | 9/20 | 0.61 |
| ▸ | PIM1 | P11309 | 8/20 | 0.61 |
| ▸ | PIM3 | Q86V86 | 8/20 | 0.61 |
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.48 |
| ▸ | TTR | P02766 | 2/20 | 0.45 |
| ▸ | NAT1 | P18440 | 1/20 | 0.45 |
| ▸ | CKS1B | P61024 | 1/20 | 0.44 |
| ▸ | SKP1 | P63208 | 1/20 | 0.44 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | BACE1 | P56817 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2428213 | 1.00 | PIM2 (0.61) | PIM2PIM1PIM3GPR119TTR | |
| SCHEMBL2428211 | 1.00 | PIM2 (0.61) | PIM2PIM1PIM3GPR119TTR | |
| SCHEMBL2424864 | 0.96 | PIM1 (0.66) | PIM2PIM1PIM3GPR119TTR | |
| SCHEMBL2428104 | 0.96 | PIM1 (0.66) | PIM2PIM1PIM3GPR119TTR | |
| SCHEMBL2429755 | 0.90 | PIM2 (0.57) | PIM2PIM1PIM3GPR119 | |
| SCHEMBL2429753 | 0.90 | PIM2 (0.57) | PIM2PIM1PIM3GPR119 | |
| SCHEMBL2429756 | 0.90 | PIM2 (0.57) | PIM2PIM1PIM3GPR119 | |
| SCHEMBL2423781 | 0.89 | PIM1 (0.60) | PIM2PIM1PIM3GPR119TTR | |
| SCHEMBL2423779 | 0.89 | PIM1 (0.60) | PIM2PIM1PIM3GPR119TTR | |
| SCHEMBL12283600 | 0.88 | PIM2 (0.61) | PIM2PIM1PIM3GPR119TTR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150051185-A1 | Chemical Compounds 251 | ASTRAZENECA AB (SE) | 2015-02-19 | — | — | US | disclosed |
| US-8901307-B2 | Chemical compounds 251 | ASTRAZENECA AB (SE) | 2014-12-02 | — | — | US | disclosed |
| US-20110218182-A1 | CHEMICAL COMPOUNDS 251 | ASTRAZENECA AB (SE) | 2011-09-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110218182-A1 | CHEMICAL COMPOUNDS 251 | PIM1, PIM3, PIM2 | PIM2 3/4885PIM1 1/4885PIM3 2/4885 |
| US-20150051185-A1 | Chemical Compounds 251 | PIM1, PIM3, PIM2 | PIM2 3/4885PIM1 1/4885PIM3 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.